KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Account Payables: 2019-2022

Historic Change in Account Payables for AbCellera Biologics (ABCL) over the last 4 years, with Dec 2022 value amounting to -$3.2 million.

  • AbCellera Biologics' Change in Account Payables was N/A to $4.1 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$12.2 million, marking a year-over-year change of. This contributed to the annual value of -$3.2 million for FY2022, which is 31.85% up from last year.
  • As of FY2022, AbCellera Biologics' Change in Account Payables stood at -$3.2 million, which was up 31.85% from -$4.6 million recorded in FY2021.
  • In the past 5 years, AbCellera Biologics' Change in Account Payables ranged from a high of $27.1 million in FY2020 and a low of -$4.6 million during FY2021.
  • For the 3-year period, AbCellera Biologics' Change in Account Payables averaged around $6.4 million, with its median value being -$3.2 million (2022).
  • Per our database at Business Quant, AbCellera Biologics' Change in Account Payables skyrocketed by 17,995.33% in 2020 and then plummeted by 117.08% in 2021.
  • Over the past 4 years, AbCellera Biologics' Change in Account Payables (Yearly) stood at $150,000 in 2019, then spiked by 17,995.33% to $27.1 million in 2020, then slumped by 117.08% to -$4.6 million in 2021, then soared by 31.85% to -$3.2 million in 2022.